LINC00886 drives ovarian cancer progression and immune escape through themiR-423-5p/TLR4/Myd88/NF-κB/PD-L1 axis, establishing its potential as both a prognostic biomarker and therapeutic target. Here, CD274 is linked to ovarian carcinoma.